2024-10-06 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis Report

**1. Stock Performance:**

Amgen Inc (AMGN) has a cumulative return of 77.55% compared to the S&P 500 (VOO) with a return of 131.01%. This results in a relative underperformance of -53.46%, which is 32.55% of the historical range of relative performance between the two. 

**Amgen Inc (AMGN)** is a leading biotechnology company developing and delivering innovative therapies in various therapeutic areas.

**2. Recent Price Movements:**

* **Closing Price:** $317.48
* **5-Day Moving Average:** $321.49
* **20-Day Moving Average:** $327.49
* **60-Day Moving Average:** $328.47

The stock price is currently trading below its short-term and long-term moving averages, suggesting potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 37.73 (suggests the stock is in oversold territory)
* **PPO:** -0.49 (indicates a bearish momentum)
* **Delta_Previous_Relative_Divergence:** -10.79 (negative value suggests a short-term decline in relative price movement)
* **Expected Return:** 0.0% (estimated 5-year expected return exceeding the S&P 500, VOO)

The technical indicators suggest a bearish bias in the short term. However, the expected return suggests potential long-term growth exceeding the market average.

**4. Recent Earnings and Outlook:**

| Date      | EPS     | Revenue |
|---|---|---|
| 2024-08-07 | 1.39    | 8.39 B$ |
| 2024-05-03 | -0.21   | 7.45 B$ |
| 2023-10-31 | 3.23    | 6.90 B$ |
| 2023-08-04 | 2.58    | 6.99 B$ |
| 2024-08-07 | 2.58    | 6.99 B$ |

The most recent earnings report for Q2 2024 showed an EPS of $1.39, exceeding analyst expectations of $1.29. The revenue also surpassed expectations, reaching $8.39 billion compared to the projected $8.15 billion. The company attributed the strong performance to growth in key products like Repatha, Otezla, and Prolia.

**5. News and Recent Issues:**

Recent market outlook for AMGN remains positive based on the strong Q2 earnings. Analyst opinions highlight the company’s strong position in the biopharmaceutical market, driven by its robust pipeline and focus on innovative therapies. 

FINBOLD reports AMGN's stock as a "Buy" based on analysts' opinions, stating the company has a strong track record of innovation and solid financial performance.

**6. Summary:**

Amgen Inc. (AMGN) is a leading biotechnology company with strong fundamentals. While the stock is currently underperforming the S&P 500, recent earnings have been positive and exceeding expectations. The company’s focus on innovation and strong pipeline suggest potential for future growth. However, the technical indicators point towards a short-term bearish bias.

**7. Recommendation:**

Investors looking for long-term growth potential in the biotechnology sector may consider AMGN. The company’s strong fundamentals, innovative pipeline, and recent strong earnings performance suggest a solid investment opportunity.  However, considering the current market sentiment and technical indicators, short-term investors should exercise caution and monitor market trends closely. 
